Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis-Reference-Cited by-同舟云学术

Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis

Published:2019-09 Issue:18 Volume:7 Page:452-452
ISSN:2305-5839
Container-title:Annals of Translational Medicine
language:
Short-container-title:Ann. Transl. Med.

Author:

Zhang Zhonghan,Zhao Yuanyuan,Lu Feiteng,Hou Xue,Ma Yuxiang,Luo Fan,Zeng Kangmei,Zhao Shen,Zhang Yaxiong,Zhou Ting,Yang Yunpeng,Fang Wenfeng,Huang Yan,Zhang Li,Zhao Hongyun

Publisher

AME Publishing Company

Subject

General Medicine

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and treatment-related adverse events of multi-targeted tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials;International Journal of Clinical Pharmacy;2022-08-11

2. The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis;Tumori Journal;2022-05-04

3. Immune checkpoint inhibitors plus anlotinib versus anlotinib alone as third-line treatment in advanced non-small-cell lung cancer: a retrospective study;Future Oncology;2021-11

4. Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models;BMC Veterinary Research;2021-10-26

5. Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study;International Journal of General Medicine;2021-06